Literature DB >> 14567023

Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.

Olivier Glehen1, François Noël Gilly.   

Abstract

Quantitative prognostic indicators for carcinomatosis and sarcomatosis are essential in the management of peritoneal surface malignancy. This need is greatly accentuated as a new comprehensive therapeutic approach emerges. The assessment of tumor histopathology, prior surgical score, lesion size, and distribution (Gilly classification and peritoneal cancer index) and the completeness of cytoreduction scores are the tools that are currently in use. Although current assessments have greatly facilitated clinical research, more precise comparisons demand improved quantitation and greater precision. Preoperative and intraoperative assessment of peritoneal surface malignancy will improve patient selection. Now more than ever, postoperative distribution and volume assessments using noninvasive modalities are needed for follow-up.

Entities:  

Mesh:

Year:  2003        PMID: 14567023     DOI: 10.1016/s1055-3207(03)00037-1

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  17 in total

1.  [Scoring systems for clinical staging of peritoneal carcinomatosis. A critical analysis].

Authors:  J Jähne; S Kübler
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

Review 2.  Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.

Authors:  Russell N Low
Journal:  J Gastrointest Oncol       Date:  2016-02

3.  Laparoscopy as a useful selection tool for patients with prior surgery and peritoneal metastases suitable for multimodality treatment strategies.

Authors:  Philipp von Breitenbuch; Thomas Boerner; Tonia Jeiter; Pompiliu Piso; Hans J Schlitt
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

4.  Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome.

Authors:  Sebastian Blaj; Sebastian Nedelcut; Max Mayr; Hubert Leebmann; Daniel Leucuta; Gabriel Glockzin; Pompiliu Piso
Journal:  Langenbecks Arch Surg       Date:  2019-07-27       Impact factor: 3.445

5.  Selection of patients and staging of peritoneal surface malignancies.

Authors:  Eddy Cotte; Guillaume Passot; François-Noël Gilly; Olivier Glehen
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 6.  Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies.

Authors:  Ramakrishnan Ayloor Seshadri
Journal:  Indian J Surg Oncol       Date:  2016-01-11

Review 7.  Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective.

Authors:  Madalyn G Neuwirth; H Richard Alexander; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 8.  Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

Authors:  Seung Yoon Yang; Jae Hyun Kang; Ho Seung Kim; Yoon Dae Han; Byung Soh Min; Kang Young Lee
Journal:  J Gastrointest Oncol       Date:  2019-12

9.  Surgery for peritoneal mesothelioma.

Authors:  Keli M Turner; Sheelu Varghese; H Richard Alexander
Journal:  Curr Treat Options Oncol       Date:  2011-06

10.  A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial.

Authors:  Gabriel Glockzin; Justine Rochon; Dirk Arnold; Sven A Lang; Frank Klebl; Florian Zeman; Michael Koller; Hans J Schlitt; Pompiliu Piso
Journal:  BMC Cancer       Date:  2013-02-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.